Online investment platform SyndicateRoom announced that Jonathan Milner won the Non-Executive Director (NED) of the Year award in the unquoted/private equity backed category. Milner, co-Founder and currently Deputy Chairman of Abcam plc, has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on the London AIM Stock exchange.
“Thank you to Peel Hunt and the other sponsors for hosting these awards, it was a great evening and I was delighted to win,” noted Milner. “The award also recognises the incredible Executive team, Chairman and other NEDs at Syndicate Room who are amongst the most talented, fun and entrepreneurial people I know – and without whom the Board would be nowhere near as effective. Special thanks goes to our CEO, Gonçalo de Vasconcelos for sponsoring me and being such an inspirational leader.”
A non-executive director of Horizon Discovery, Frontier Developments, SyndicateRoom and GeoSpock, Milner is also Chairman of Axol Bioscience, Cambridge Allergy Therapy, PhoreMost, Repositive and DefiniGEN, and sits on the advisory boards of Desktop Genetics and Healx.
As non-executive director of SyndicateRoom, Milner brings his entrepreneurial experience and knowledge to the Board, focusing the executive management team on its core business, “encouraging them to carry out fewer, but better quality projects, delivered brilliantly.” Thanks to his active role in the business, SyndicateRoom has delivered on its strategic vision and returned to high growth, doubling, and then trebling revenues.
“It’s fantastic to see Jonathan acknowledged by this prestigious organisation,” added SyndicateRoom CEO Gonçalo de Vasconcelos. “As an experienced and ultra-successful entrepreneur, he’s an inspiration to work with. But beyond that, the great thing about Jonathan is just how humble he is and how good he is with other people. He asks brilliant questions and contributes with great ideas but he is always open to be proven wrong and willing to openly accept other people’s ideas. This gives room to inspiring, engaging and open conversations and discussions at board level without egos clouding good reasoning.”
Milner gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath. From 1992–95, he was a post-doctoral researcher at Bath, following which he worked at the University of Cambridge in the lab of Professor Tony Kouzarides researching the molecular basis of breast cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies, and in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides.